Sex Differences In Troponin In Covid-19 Patients

Katelyn A. Bruno,DeLisa Fairweather

DOI: https://doi.org/10.1016/j.cardfail.2023.10.181

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Sex differences are important across many diseases including cancer, cardiovascular, autoimmune, and infectious diseases. There have been numerous studies looking at biomarkers of disease finding that biomarkers can have sex-specific cut-offs as well as predictability. Previous reports indicate that more men develop COVID-19 and have more severe disease, which may indicate a differential response to SARS-CoV-2. Hypothesis We hypothesized that patients with elevated troponin (TnT) levels would have increased mortality due to COVID-19 and present with more cardiovascular serious adverse events and that this predictive biomarker would have sex-specific findings. Methods The United States (US) convalescent plasma expanded access program (EAP) provided access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2. The EAP treated 94,287 patients across the US from April-August 2020 this study looks at a subset of 1,529 patients (39% female) for which we have troponin laboratory data. We assessed sex differences in troponin lab's effect on mortality and cardiovascular serious adverse events in this patient population. Results Of these patients, 29% of female and 34% of male patients died within 30 days of transfusion. Of females who had TnT levels >10, 14.8% died within 7 days and 36.1% died within 30 days compared to 6.9% (p=0.01) and 16.9% (p<0.001), respectively, in females without elevated troponin. Of males who had TnT levels >15 16.5% died within 7 days and 40.6% died within 30 days compared to 11.9% (p=0.13) and 28.4% (p=0.002), respectively, in males without elevated troponin. Females with elevated troponin were 2.4 and 2.8 times more likely to die at 7 and 30 days and males with elevated troponin were males were 1.7 more likely to die at 30 days only. Pre-existing cardiovascular disease or prior use of ACE inhibitors or ARBs did not influence the troponin levels during COVID infection. Conclusions We and others have found that sex differences exist in the prevalence and severity of COVID-19 patients. Specifically understanding the cardiovascular risks associated with COVID and how troponin labs relate to the risk of mortality and adverse events due to COVID is important for clinical decision making. Understanding sex differences in COVID-19 may lead to a more individualized approach that will allow more informative patient care during the pandemic and inform future outbreaks.

cardiac & cardiovascular systems